drugset / Trial / NCT02223832

Study to Evaluate the Pharmacokinetics, Tolerability, and Safety of ACT-128800 in Japanese and Caucasian Healthy Male and Female Subjects

NCT02223832

Phase 1 Completed 20 enrolled Actelion
NaSingle-groupOpen-label

Summary

This is a study to evaluate the relative pharmacokinetic properties and the tolerability and safety of ACT-128800 in Japanese and Caucasian healthy male and female subjects after single-dose administration.

Timeline

Start
2009-02
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Ponesimod Small molecule 40 mg Oral

Indications

No indication recorded.